TFRC

Chr 3AR

transferrin receptor

Also known as: CD71, IMD46, T9, TFR, TFR1, TR, TRFR, p90

This gene encodes a cell surface receptor necessary for cellular iron uptake by the process of receptor-mediated endocytosis. This receptor is required for erythropoiesis and neurologic development. Multiple alternatively spliced variants have been identified. [provided by RefSeq, Sep 2015]

OMIMResearchGenerating clinical summary…
DNmechanismARLOEUF 0.581 OMIM phenotype
Clinical SummaryTFRC
🧬
Gene-Disease Validity (ClinGen)
TFRC-related combined immunodeficiency · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?
0.58LOEUF
pLI 0.000
Z-score 3.58
OE 0.37 (0.240.58)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
0.60Z-score
OE missense 0.92 (0.841.00)
380 obs / 414.7 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.37 (0.240.58)
00.351.4
Missense OE?0.92 (0.841.00)
00.61.4
Synonymous OE?1.00
01.21.6
LoF obs/exp: 14 / 37.7Missense obs/exp: 380 / 414.7Syn Z: -0.00
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
limitedTFRC-related combined immunodeficiencyOTHERAR

This gene — mechanism propensity

Predictions shown for reference only — model trained on dominant genes, not applicable to AR conditions.

DN
0.6357th %ile
GOF
0.5856th %ile
LOF
0.3065th %ile

The Badonyi & Marsh prediction model was trained exclusively on dominant disease genes. Predictions are not reliable for genes with autosomal recessive inheritance and are shown at reduced opacity for reference only.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

TFRC · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Weight GainAnemia, Iron DeficiencyBirth Weight

Egg Intervention During Pregnancy in Indonesia

ACTIVE NOT RECRUITING
NCT04694235Phase NASEAMEO Regional Centre for Food and NutritionStarted 2021-02-12
Egg intervention
Chronic Myeloid Leukemia, BCR/ABL-Positive

Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission

RECRUITING
NCT05439889National Taiwan University HospitalStarted 2022-08-11
Sickle Cell Disease

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

ACTIVE NOT RECRUITING
NCT04293185Phase PHASE3Genetix Biotherapeutics Inc.Started 2020-02-14
bb1111
Chronic Myeloid Leukemia, Chronic PhaseAdult CMLLeukemia, Myeloid

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

RECRUITING
NCT05143840Phase PHASE2University of Alabama at BirminghamStarted 2022-04-22
Single Agent AsciminibLow TKIElective Free Treatment
Malnutrition PregnancyMalnutrition in ChildrenMalnutrition (Calorie)

Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories

RECRUITING
NCT07195006University of ZimbabweStarted 2025-01-27
Malnutrition in pregnancy as exposurePoor WASH living conditions as exposure
Acute Coronary Syndromes (ACS)Iron DeficienciesElderly (People Aged 65 or More)

Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome

RECRUITING
NCT07476859Phase PHASE4Fundación para la Investigación del Hospital Clínico de ValenciaStarted 2026-03-05
Ferric Carboxymaltose Injection [Ferinject]
Micronutrient Status

Micronutrient Dose Response Study in Bangladesh

ACTIVE NOT RECRUITING
NCT06081114Phase NAJohns Hopkins Bloomberg School of Public HealthStarted 2023-10-22
Micronutrient Supplement
VEXAS Syndrome

Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection

RECRUITING
NCT06377462Technische Universität DresdenStarted 2024-03-13
Transfusion-dependent Beta-Thalassemia

Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia

NOT YET RECRUITING
NCT07680803Phase PHASE2Fondazione TelethonStarted 2026-07
FT007
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

ACTIVE NOT RECRUITING
NCT05456191Phase PHASE3Novartis PharmaceuticalsStarted 2022-11-21
AsciminibNilotinib
Anemia, Iron DeficiencyIron Overload

Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption

RECRUITING
NCT06146608Cornell UniversityStarted 2023-01-15
Chronic Myeloid Leukemia, Chronic PhaseWithdrawal;Drug

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia

ACTIVE NOT RECRUITING
NCT04147533Phase PHASE2Masaryk UniversityStarted 2020-06-16
Imatinib withdrawalDasatinibNilotinib